| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 53 | 2021 | 778 | 6.350 |
Why?
|
| Prostate-Specific Antigen | 27 | 2020 | 138 | 2.700 |
Why?
|
| Urinary Bladder Neoplasms | 19 | 2021 | 138 | 2.270 |
Why?
|
| Kidney Neoplasms | 19 | 2015 | 206 | 2.070 |
Why?
|
| Prostatectomy | 15 | 2021 | 87 | 1.840 |
Why?
|
| Early Detection of Cancer | 11 | 2020 | 439 | 1.460 |
Why?
|
| Carcinoma, Renal Cell | 10 | 2011 | 110 | 1.220 |
Why?
|
| Prostate | 9 | 2016 | 116 | 1.200 |
Why?
|
| Biomarkers, Tumor | 10 | 2020 | 508 | 0.960 |
Why?
|
| Male | 99 | 2021 | 37281 | 0.880 |
Why?
|
| Mass Screening | 14 | 2018 | 837 | 0.810 |
Why?
|
| Vena Cava, Inferior | 2 | 2014 | 41 | 0.780 |
Why?
|
| Aged | 63 | 2021 | 14842 | 0.730 |
Why?
|
| Humans | 116 | 2021 | 68525 | 0.710 |
Why?
|
| Genome-Wide Association Study | 10 | 2016 | 240 | 0.710 |
Why?
|
| Middle Aged | 73 | 2021 | 21119 | 0.670 |
Why?
|
| Digital Rectal Examination | 10 | 2018 | 11 | 0.630 |
Why?
|
| Hospitals | 1 | 2019 | 265 | 0.580 |
Why?
|
| Carcinoma, Transitional Cell | 4 | 2014 | 41 | 0.570 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2016 | 785 | 0.560 |
Why?
|
| Azasteroids | 2 | 2012 | 4 | 0.560 |
Why?
|
| Ovarian Neoplasms | 5 | 2015 | 267 | 0.540 |
Why?
|
| Treatment Outcome | 26 | 2021 | 7028 | 0.510 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2017 | 2222 | 0.500 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2012 | 14 | 0.490 |
Why?
|
| Prognosis | 14 | 2020 | 2093 | 0.470 |
Why?
|
| Testicular Neoplasms | 4 | 2015 | 27 | 0.460 |
Why?
|
| Positron-Emission Tomography | 3 | 2009 | 160 | 0.410 |
Why?
|
| Colorectal Neoplasms | 4 | 2015 | 560 | 0.410 |
Why?
|
| BCG Vaccine | 2 | 2017 | 12 | 0.400 |
Why?
|
| Risk Factors | 21 | 2020 | 5719 | 0.390 |
Why?
|
| Meningeal Neoplasms | 3 | 2016 | 42 | 0.380 |
Why?
|
| Neoplasm Grading | 9 | 2018 | 110 | 0.380 |
Why?
|
| Lung Neoplasms | 6 | 2015 | 1172 | 0.380 |
Why?
|
| Meningioma | 3 | 2016 | 54 | 0.370 |
Why?
|
| Incidence | 13 | 2018 | 1582 | 0.360 |
Why?
|
| Biopsy | 8 | 2016 | 539 | 0.340 |
Why?
|
| Genetic Loci | 3 | 2014 | 59 | 0.340 |
Why?
|
| Female | 44 | 2020 | 38015 | 0.340 |
Why?
|
| Patient Participation | 2 | 2021 | 145 | 0.340 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 28 | 0.330 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2005 | 7 | 0.330 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2016 | 627 | 0.330 |
Why?
|
| Cystectomy | 5 | 2019 | 13 | 0.330 |
Why?
|
| Time Factors | 12 | 2021 | 4655 | 0.320 |
Why?
|
| Laparoscopy | 3 | 2011 | 237 | 0.320 |
Why?
|
| Retrospective Studies | 22 | 2019 | 7264 | 0.320 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 306 | 0.320 |
Why?
|
| Neoplasm Staging | 11 | 2019 | 799 | 0.320 |
Why?
|
| Survival Rate | 8 | 2020 | 1055 | 0.320 |
Why?
|
| Finasteride | 1 | 2007 | 2 | 0.320 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2007 | 12 | 0.310 |
Why?
|
| Leiomyomatosis | 1 | 2007 | 3 | 0.310 |
Why?
|
| Anticarcinogenic Agents | 1 | 2007 | 52 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2018 | 929 | 0.300 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 3256 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 2 | 3 | 2011 | 14 | 0.300 |
Why?
|
| Signal Transduction | 2 | 2009 | 2688 | 0.300 |
Why?
|
| Uterine Neoplasms | 1 | 2007 | 99 | 0.300 |
Why?
|
| Carotid Artery, Internal | 2 | 2020 | 85 | 0.300 |
Why?
|
| Adult | 31 | 2019 | 21375 | 0.300 |
Why?
|
| Body Mass Index | 4 | 2013 | 866 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2021 | 536 | 0.290 |
Why?
|
| Prostatic Hyperplasia | 3 | 2015 | 25 | 0.290 |
Why?
|
| Predictive Value of Tests | 10 | 2018 | 1465 | 0.280 |
Why?
|
| Brain Neoplasms | 5 | 2014 | 371 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2017 | 444 | 0.280 |
Why?
|
| Kidney Pelvis | 2 | 2003 | 12 | 0.280 |
Why?
|
| Ureteral Obstruction | 2 | 2003 | 25 | 0.280 |
Why?
|
| Postoperative Complications | 9 | 2021 | 1615 | 0.280 |
Why?
|
| Urologic Neoplasms | 1 | 2005 | 14 | 0.280 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2006 | 85 | 0.270 |
Why?
|
| Risk Assessment | 7 | 2018 | 2004 | 0.260 |
Why?
|
| Carotid Stenosis | 3 | 2020 | 163 | 0.260 |
Why?
|
| Veterans | 4 | 2021 | 904 | 0.260 |
Why?
|
| Robotics | 3 | 2014 | 56 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 212 | 0.250 |
Why?
|
| Aged, 80 and over | 12 | 2019 | 4843 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2014 | 11 | 0.250 |
Why?
|
| Pelvic Neoplasms | 1 | 2004 | 13 | 0.250 |
Why?
|
| Cohort Studies | 11 | 2021 | 2356 | 0.250 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 659 | 0.240 |
Why?
|
| Hypercalcemia | 1 | 2004 | 34 | 0.240 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2004 | 25 | 0.240 |
Why?
|
| Radiosurgery | 3 | 2016 | 66 | 0.240 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2003 | 6 | 0.240 |
Why?
|
| United States | 17 | 2018 | 7335 | 0.240 |
Why?
|
| Case-Control Studies | 10 | 2020 | 1548 | 0.240 |
Why?
|
| Obesity | 2 | 2009 | 1074 | 0.230 |
Why?
|
| Urothelium | 2 | 2014 | 22 | 0.230 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 132 | 0.230 |
Why?
|
| Surgical Staplers | 1 | 2002 | 4 | 0.220 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 375 | 0.220 |
Why?
|
| Urinary Diversion | 2 | 2012 | 16 | 0.220 |
Why?
|
| Proportional Hazards Models | 7 | 2021 | 791 | 0.220 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 235 | 0.210 |
Why?
|
| Erectile Dysfunction | 2 | 2021 | 22 | 0.200 |
Why?
|
| Metformin | 1 | 2021 | 63 | 0.200 |
Why?
|
| Autocrine Communication | 1 | 2021 | 37 | 0.200 |
Why?
|
| Titanium | 1 | 2002 | 118 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2011 | 17 | 0.200 |
Why?
|
| Prospective Studies | 10 | 2021 | 3702 | 0.200 |
Why?
|
| Urinary Incontinence | 2 | 2021 | 67 | 0.200 |
Why?
|
| Lymph Node Excision | 3 | 2011 | 91 | 0.200 |
Why?
|
| Exercise | 2 | 2018 | 657 | 0.200 |
Why?
|
| Disease Progression | 5 | 2016 | 1037 | 0.200 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 100 | 0.200 |
Why?
|
| Decision Support Techniques | 2 | 2021 | 191 | 0.190 |
Why?
|
| Brachytherapy | 2 | 2013 | 79 | 0.180 |
Why?
|
| Biopsy, Needle | 6 | 2017 | 191 | 0.180 |
Why?
|
| Neoplasms | 3 | 2016 | 1660 | 0.180 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 83 | 0.180 |
Why?
|
| Data Accuracy | 1 | 2019 | 10 | 0.170 |
Why?
|
| Marital Status | 1 | 2019 | 65 | 0.170 |
Why?
|
| Nephrectomy | 3 | 2011 | 103 | 0.170 |
Why?
|
| Patient Selection | 3 | 2015 | 592 | 0.170 |
Why?
|
| Adenocarcinoma | 2 | 2012 | 475 | 0.170 |
Why?
|
| Comorbidity | 7 | 2019 | 1425 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2019 | 125 | 0.170 |
Why?
|
| Cerebral Revascularization | 2 | 2020 | 45 | 0.160 |
Why?
|
| Quality of Life | 4 | 2018 | 1515 | 0.160 |
Why?
|
| Postoperative Care | 1 | 2019 | 163 | 0.160 |
Why?
|
| Nomograms | 1 | 2017 | 19 | 0.160 |
Why?
|
| Self-Management | 1 | 2019 | 82 | 0.160 |
Why?
|
| Trichomonas Infections | 1 | 2017 | 14 | 0.160 |
Why?
|
| Carcinoma | 2 | 2012 | 215 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 109 | 0.150 |
Why?
|
| Interferon-alpha | 1 | 2017 | 46 | 0.150 |
Why?
|
| Survivorship | 1 | 2017 | 20 | 0.150 |
Why?
|
| Image-Guided Biopsy | 1 | 2016 | 17 | 0.150 |
Why?
|
| Bacteriochlorophylls | 1 | 2016 | 1 | 0.140 |
Why?
|
| Stroke | 3 | 2020 | 2161 | 0.140 |
Why?
|
| Veterans Health | 1 | 2017 | 61 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 3 | 0.140 |
Why?
|
| Dutasteride | 2 | 2012 | 2 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 114 | 0.140 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2012 | 9 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2016 | 18 | 0.140 |
Why?
|
| Ablation Techniques | 1 | 2016 | 33 | 0.140 |
Why?
|
| Medical Oncology | 2 | 2014 | 110 | 0.140 |
Why?
|
| Photochemotherapy | 1 | 2016 | 59 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 4 | 2021 | 369 | 0.140 |
Why?
|
| Cerebral Cortex | 2 | 2013 | 415 | 0.130 |
Why?
|
| Genetic Therapy | 1 | 2017 | 291 | 0.130 |
Why?
|
| Nocturia | 1 | 2015 | 3 | 0.130 |
Why?
|
| Comparative Effectiveness Research | 4 | 2018 | 36 | 0.130 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 13 | 0.130 |
Why?
|
| Preoperative Care | 3 | 2017 | 275 | 0.130 |
Why?
|
| Administration, Intravesical | 2 | 2017 | 8 | 0.130 |
Why?
|
| Cyclin E | 1 | 2014 | 19 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 756 | 0.130 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2015 | 53 | 0.130 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 35 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2014 | 9 | 0.130 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 1046 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 33 | 0.130 |
Why?
|
| Smoking | 5 | 2015 | 1449 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 3 | 2009 | 296 | 0.120 |
Why?
|
| Self Care | 1 | 2017 | 252 | 0.120 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2014 | 52 | 0.120 |
Why?
|
| Carotid Artery, External | 1 | 2014 | 5 | 0.120 |
Why?
|
| Air Travel | 1 | 2013 | 2 | 0.120 |
Why?
|
| Tissue Array Analysis | 2 | 2015 | 53 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2013 | 28 | 0.120 |
Why?
|
| Chromosome Deletion | 1 | 2013 | 41 | 0.120 |
Why?
|
| Astrocytoma | 1 | 2013 | 30 | 0.120 |
Why?
|
| Oligodendroglioma | 1 | 2013 | 18 | 0.120 |
Why?
|
| Ultrasonography, Interventional | 4 | 2007 | 119 | 0.120 |
Why?
|
| Telomerase | 1 | 2014 | 85 | 0.120 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 349 | 0.120 |
Why?
|
| Reproductive History | 1 | 2013 | 8 | 0.120 |
Why?
|
| Ileal Neoplasms | 1 | 2012 | 5 | 0.110 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 45 | 0.110 |
Why?
|
| Postmenopause | 1 | 2013 | 92 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2013 | 78 | 0.110 |
Why?
|
| Logistic Models | 3 | 2013 | 1419 | 0.110 |
Why?
|
| Ischemic Attack, Transient | 1 | 2013 | 167 | 0.110 |
Why?
|
| Salvage Therapy | 2 | 2014 | 82 | 0.110 |
Why?
|
| Databases, Factual | 3 | 2021 | 621 | 0.110 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.110 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2011 | 2 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2011 | 16 | 0.100 |
Why?
|
| Retroperitoneal Space | 1 | 2011 | 7 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 307 | 0.100 |
Why?
|
| Intestinal Neoplasms | 1 | 2011 | 30 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 301 | 0.100 |
Why?
|
| Sensitivity and Specificity | 5 | 2017 | 1753 | 0.100 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2011 | 58 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2010 | 2323 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 61 | 0.100 |
Why?
|
| Patient Compliance | 3 | 2009 | 402 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 201 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 81 | 0.100 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2011 | 52 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 32 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2010 | 18 | 0.100 |
Why?
|
| Telemedicine | 1 | 2019 | 699 | 0.090 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2010 | 5 | 0.090 |
Why?
|
| Universities | 1 | 2011 | 191 | 0.090 |
Why?
|
| Energy Metabolism | 2 | 2002 | 222 | 0.090 |
Why?
|
| Pedigree | 2 | 2007 | 159 | 0.090 |
Why?
|
| Somatosensory Cortex | 1 | 2009 | 22 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2014 | 617 | 0.090 |
Why?
|
| Cognition | 1 | 2014 | 512 | 0.090 |
Why?
|
| Linkage Disequilibrium | 3 | 2016 | 91 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 503 | 0.090 |
Why?
|
| Microdissection | 1 | 2009 | 15 | 0.090 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 32 | 0.090 |
Why?
|
| Spleen | 1 | 2010 | 301 | 0.090 |
Why?
|
| Protein Interaction Mapping | 1 | 2009 | 62 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 3 | 2018 | 186 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 378 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 274 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2009 | 113 | 0.080 |
Why?
|
| Brain Mapping | 2 | 2009 | 531 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2009 | 218 | 0.080 |
Why?
|
| ROC Curve | 3 | 2017 | 392 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2017 | 714 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 951 | 0.080 |
Why?
|
| Motor Cortex | 1 | 2009 | 158 | 0.080 |
Why?
|
| Risk | 3 | 2014 | 563 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2007 | 42 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 648 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 329 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2017 | 880 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2007 | 216 | 0.070 |
Why?
|
| Bias | 1 | 2007 | 148 | 0.070 |
Why?
|
| Cancer Survivors | 2 | 2019 | 145 | 0.070 |
Why?
|
| Cryosurgery | 1 | 2006 | 53 | 0.070 |
Why?
|
| Genotype | 3 | 2013 | 785 | 0.070 |
Why?
|
| Young Adult | 5 | 2019 | 5708 | 0.070 |
Why?
|
| Recurrence | 3 | 2020 | 948 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2017 | 238 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 424 | 0.070 |
Why?
|
| Vasospasm, Intracranial | 1 | 2005 | 16 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 546 | 0.070 |
Why?
|
| Prevalence | 3 | 2015 | 1609 | 0.070 |
Why?
|
| Surgical Instruments | 2 | 2002 | 44 | 0.070 |
Why?
|
| Palpation | 1 | 2005 | 21 | 0.070 |
Why?
|
| Stents | 1 | 2010 | 657 | 0.070 |
Why?
|
| Urogenital Neoplasms | 1 | 2005 | 9 | 0.070 |
Why?
|
| Registries | 3 | 2015 | 730 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 2005 | 136 | 0.070 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2005 | 61 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 1054 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2014 | 207 | 0.060 |
Why?
|
| Oxygen Consumption | 2 | 2002 | 258 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2007 | 446 | 0.060 |
Why?
|
| Computational Biology | 2 | 2016 | 190 | 0.060 |
Why?
|
| Lymph Nodes | 2 | 2017 | 258 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2005 | 403 | 0.060 |
Why?
|
| Haplotypes | 2 | 2014 | 174 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2021 | 411 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 250 | 0.050 |
Why?
|
| Suture Techniques | 1 | 2002 | 75 | 0.050 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2002 | 7 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 693 | 0.050 |
Why?
|
| Neuronavigation | 1 | 2002 | 8 | 0.050 |
Why?
|
| Craniotomy | 1 | 2002 | 33 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1851 | 0.050 |
Why?
|
| SEER Program | 2 | 2012 | 150 | 0.050 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 17 | 0.050 |
Why?
|
| Necrosis | 2 | 2014 | 239 | 0.050 |
Why?
|
| Radiotherapy | 2 | 2014 | 86 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2021 | 122 | 0.050 |
Why?
|
| Patient Preference | 1 | 2021 | 57 | 0.050 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2011 | 4 | 0.050 |
Why?
|
| Chromosome Mapping | 2 | 2011 | 188 | 0.050 |
Why?
|
| Reoperation | 1 | 2002 | 467 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2002 | 190 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 195 | 0.050 |
Why?
|
| Glioma | 1 | 2002 | 140 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2003 | 1199 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 146 | 0.050 |
Why?
|
| RNA Interference | 1 | 2021 | 266 | 0.050 |
Why?
|
| Adolescent | 5 | 2019 | 8903 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 135 | 0.050 |
Why?
|
| Syndrome | 1 | 2020 | 255 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 955 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 434 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2021 | 383 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2002 | 268 | 0.040 |
Why?
|
| Decision Making | 1 | 2021 | 410 | 0.040 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 32 | 0.040 |
Why?
|
| Cholic Acids | 1 | 2017 | 8 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2018 | 85 | 0.040 |
Why?
|
| Disaccharides | 1 | 2017 | 9 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2019 | 200 | 0.040 |
Why?
|
| Urination Disorders | 1 | 2017 | 20 | 0.040 |
Why?
|
| Antibodies, Protozoan | 1 | 2017 | 15 | 0.040 |
Why?
|
| Age Factors | 2 | 2013 | 1860 | 0.040 |
Why?
|
| Trichomonas vaginalis | 1 | 2017 | 22 | 0.040 |
Why?
|
| Mortality | 1 | 2018 | 162 | 0.040 |
Why?
|
| American Cancer Society | 1 | 2016 | 2 | 0.040 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2016 | 3 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 319 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2010 | 2798 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2017 | 295 | 0.040 |
Why?
|
| Hepatitis Viruses | 1 | 2016 | 1 | 0.040 |
Why?
|
| Virus Integration | 1 | 2016 | 5 | 0.040 |
Why?
|
| Self Report | 1 | 2018 | 370 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2017 | 311 | 0.040 |
Why?
|
| Herpesviridae | 1 | 2016 | 11 | 0.040 |
Why?
|
| Viruses | 1 | 2016 | 14 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 34 | 0.040 |
Why?
|
| Fatigue | 1 | 2017 | 132 | 0.040 |
Why?
|
| Health Services | 1 | 2017 | 87 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 1849 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2017 | 172 | 0.040 |
Why?
|
| Social Support | 1 | 2019 | 423 | 0.040 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 29 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 40 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2016 | 93 | 0.030 |
Why?
|
| Hemodynamics | 2 | 2014 | 705 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 167 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 376 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2016 | 87 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 103 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2015 | 35 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 742 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 204 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2015 | 44 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 47 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2016 | 220 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 332 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1174 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 100 | 0.030 |
Why?
|
| Estrone | 1 | 2014 | 9 | 0.030 |
Why?
|
| Algorithms | 2 | 2013 | 1194 | 0.030 |
Why?
|
| Transcriptome | 1 | 2016 | 164 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 134 | 0.030 |
Why?
|
| Physical Examination | 2 | 2005 | 152 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2016 | 453 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 33 | 0.030 |
Why?
|
| Testosterone | 1 | 2014 | 96 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2014 | 237 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 129 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 30 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2014 | 108 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 104 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 57 | 0.030 |
Why?
|
| Menarche | 1 | 2013 | 18 | 0.030 |
Why?
|
| Estradiol | 1 | 2014 | 176 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2013 | 49 | 0.030 |
Why?
|
| Alleles | 1 | 2014 | 386 | 0.030 |
Why?
|
| Contraceptives, Oral | 1 | 2013 | 28 | 0.030 |
Why?
|
| Estrogens | 1 | 2014 | 173 | 0.030 |
Why?
|
| Parity | 1 | 2013 | 71 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2013 | 31 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2013 | 64 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 38 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2014 | 192 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 163 | 0.030 |
Why?
|
| Contrast Media | 2 | 2007 | 594 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2012 | 26 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 729 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 766 | 0.030 |
Why?
|
| HapMap Project | 1 | 2011 | 1 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 2 | 2002 | 40 | 0.030 |
Why?
|
| Gene Expression | 1 | 2014 | 770 | 0.030 |
Why?
|
| Washington | 1 | 2011 | 27 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2012 | 84 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 99 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 517 | 0.030 |
Why?
|
| Sample Size | 1 | 2011 | 79 | 0.020 |
Why?
|
| Forecasting | 1 | 2012 | 277 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2013 | 307 | 0.020 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2010 | 11 | 0.020 |
Why?
|
| Brain | 1 | 2002 | 2175 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 281 | 0.020 |
Why?
|
| Spain | 1 | 2010 | 34 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 319 | 0.020 |
Why?
|
| Genome, Human | 1 | 2010 | 62 | 0.020 |
Why?
|
| Medical Records | 1 | 2011 | 121 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 561 | 0.020 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2010 | 8 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 195 | 0.020 |
Why?
|
| Unnecessary Procedures | 1 | 2010 | 49 | 0.020 |
Why?
|
| Kidney Calculi | 1 | 2010 | 19 | 0.020 |
Why?
|
| Somatosensory Disorders | 1 | 2009 | 4 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 274 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2009 | 53 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 2009 | 61 | 0.020 |
Why?
|
| Hemodilution | 1 | 2009 | 9 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 689 | 0.020 |
Why?
|
| Hand | 1 | 2009 | 90 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1139 | 0.020 |
Why?
|
| Muscles | 1 | 2009 | 158 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 8472 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 81 | 0.020 |
Why?
|
| Paresis | 1 | 2009 | 78 | 0.020 |
Why?
|
| Movement | 1 | 2009 | 179 | 0.020 |
Why?
|
| Family | 1 | 2010 | 293 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 83 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2010 | 295 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2009 | 213 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2008 | 132 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 242 | 0.020 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2007 | 5 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2013 | 2453 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 2008 | 150 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2007 | 63 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2009 | 219 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 2891 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1039 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 3185 | 0.020 |
Why?
|
| Organ Size | 1 | 2006 | 242 | 0.020 |
Why?
|
| Melanoma | 1 | 2009 | 335 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2005 | 13 | 0.020 |
Why?
|
| Rectum | 1 | 2005 | 62 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2005 | 76 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2005 | 61 | 0.020 |
Why?
|
| Motor Activity | 1 | 2008 | 621 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 334 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2005 | 89 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2005 | 143 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 177 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 194 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 20877 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2005 | 284 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 848 | 0.010 |
Why?
|
| Child | 1 | 2013 | 6400 | 0.010 |
Why?
|
| Bone Nails | 1 | 2002 | 32 | 0.010 |
Why?
|
| Glasgow Coma Scale | 1 | 2002 | 65 | 0.010 |
Why?
|
| Skull | 1 | 2002 | 63 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2002 | 78 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2002 | 168 | 0.010 |
Why?
|
| Awareness | 1 | 2002 | 81 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2002 | 172 | 0.010 |
Why?
|
| Proteins | 1 | 2005 | 473 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2002 | 240 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2077 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2002 | 244 | 0.010 |
Why?
|
| Homeostasis | 1 | 2002 | 291 | 0.010 |
Why?
|
| Oxygen | 1 | 2002 | 386 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 1213 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2005 | 665 | 0.010 |
Why?
|
| Critical Care | 1 | 2002 | 263 | 0.010 |
Why?
|
| Kidney | 1 | 2003 | 945 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 1533 | 0.010 |
Why?
|
| Epilepsy | 1 | 2002 | 336 | 0.010 |
Why?
|